Inncardio

Inncardio, Inc. was a biotechnology company founded by Bioaccelerate Holdings Inc. in the mid-2000s, focused on the acquisition and development of therapies for cardiovascular and metabolic diseases. The company's strategy centered on creating novel formulations of established drugs to improve efficacy and minimize side effects, as well as developing new chemical entities. A key component of its development efforts was a partnership with Sigmoid Biotechnologies to utilize the LEDDS (Liquid Emulsion Drug Delivery System) technology for controlled-release formulations. In late 2006, the company underwent a reverse merger with Long-e International Group, subsequently changing its name to Long-e International, Inc. and shifting its business focus to the automotive electronics industry.